In failing hearts, miR-21 increases in fibroblasts, boosting ERK–MAP kinase activity by inhibiting Spry1, which controls fibroblast survival, growth factor secretion, interstitial fibrosis, and cardiac hypertrophy. This evidence concerns the gene SPRY1 and cardiac hypertrophy.